var data={"title":"Gadoterate meglumine: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Gadoterate meglumine: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/542310?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=gadoterate-meglumine-patient-drug-information\" class=\"drug drug_patient\">see &quot;Gadoterate meglumine: Patient drug information&quot;</a> and <a href=\"topic.htm?path=gadoterate-meglumine-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Gadoterate meglumine: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49334639\" class=\"block spa drugH1Div\"><span class=\"drugH1\">Special Alerts</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Gadolinium-Based Contrast Agents Safety Alert</span>\n      <span class=\"collapsible-date\">December 2017</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:0em;margin-top:2em;\">The FDA is requiring a new class warning, new Medication Guide, and other safety measures for all gadolinium-based contrast agents (GBCAs) for magnetic resonance imaging (MRI) regarding gadolinium remaining in patients' bodies, including the brain, for months to years after receiving these drugs. However, because gadolinium retention has not been directly linked to adverse health effects in patients with normal kidney function, the FDA has concluded that the benefit of all approved GBCAs continues to outweigh any potential risks.</p>\n        <p style=\"text-indent:0em;margin-top:2em;\">Health care providers should consider the retention characteristics of each agent when choosing a GBCA for patients who may be at higher risk for gadolinium retention, including those requiring multiple lifetime doses, pregnant women, children, and patients with inflammatory conditions. Although providers should minimize repeated GBCA imaging studies when possible, particularly closely spaced MRI studies, necessary GBCA MRI scans should not be avoided or deferred. Health care providers should ensure that patients carefully read the new Medication Guide before receiving a GBCA.</p>\n        <p style=\"text-indent:0em;margin-top:2em;\">Further information can be found at <a target=\"_blank\" href=\"https://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm589580.htm&amp;token=Do7F8mUMHZ5/s1VO2ToSVQc0FIvxuJct8s2XQAmrP6Zclph1jTE4ohbEGIUswzhaMGIPSHysMdF12NhZ7JwyN2R2Gou2JaOgN/abp607dqC+GD0vx8r77GARzw9XI5at9GGki/68NHngWSah5+Qw3g==&amp;TOPIC_ID=88898\" target=\"_blank\">https://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm589580.htm</a>.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Gadolinium-Based Contrast Agents for MRI Safety Review</span>\n      <span class=\"collapsible-date\">May 2017</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:0em;\">The FDA identified no evidence to date that gadolinium retention in the brain from any of the gadolinium-based contrast agents (GBCAs) for magnetic resonance imaging (MRI) is harmful, including GBCAs associated with higher retention of gadolinium, and therefore, restricting GBCA use is not warranted at this time. All GBCAs may be associated with some gadolinium retention in the brain and other body tissues. The FDA will continue to assess the safety of GBCAs and plan to have a public meeting to discuss this issue in the future. Health care providers should limit GBCA use to circumstances in which additional information provided by the contrast agent is necessary, and assess the necessity of repetitive MRIs with GBCAs. Retention of gadolinium affects only GBCAs, and does not apply to other types of scanning agents used for other imaging procedures, such as those that are iodine-based or radioisotopes.</p>\n        <p style=\"text-indent:0em;\">Further information may be found at <a target=\"_blank\" href=\"https://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm559709.htm?source=govdelivery&utm_medium=email&utm_source=govdelivery&amp;token=A+6oUwz5nYUZc3lEr1kP7BtLKnUrs6ODZsjcPV9KMyX4JnZOaUZ4v4WHkLmi0EKWvCCQ6RRR7uNYUokCfgeVc768Ba4J+HWDjLlRBCiBxtRZyZ58s7DOgXBX5msP35tg66ICqZf/qPRDl03GsgPnru8Lm2GCbUta4wNEC7od5KHrTCF6F4YU6ugBKJqroXAu&amp;TOPIC_ID=88898\" target=\"_blank\">https://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm559709.htm?source=govdelivery&amp;utm_medium=email&amp;utm_source=govdelivery</a>.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16424023\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Nephrogenic systemic fibrosis:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Gadolinium-based contrast agents (GBCAs) increase the risk of nephrogenic systemic fibrosis among patients with impaired elimination of the drugs. Avoid use of GBCAs in these patients unless the diagnostic information is essential and not available with noncontrasted magnetic resonance imaging (MRI) or other modalities. Nephrogenic systemic fibrosis may result in fatal or debilitating fibrosis affecting the skin, muscle, and internal organs. The risk of nephrogenic systemic fibrosis appears highest among patients with chronic, severe kidney disease (glomerular filtration rate [GFR] &lt;30 mL/minute/1.73 m<sup>2</sup>) or acute kidney injury. Screen patients for acute kidney injury and other conditions that may reduce renal function. For patients at risk of chronically reduced renal function (eg, age &gt;60 years, hypertension, diabetes), estimate the GFR through laboratory testing. For patients at highest risk of nephrogenic systemic fibrosis, do not exceed the recommended dose, and allow a sufficient period of time for elimination of the drug from the body prior to any readministration.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F21879247\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Dotarem</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50906584\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Dotarem</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16424027\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Diagnostic Agent;</li>\n      <li>\n        Gadolinium-Containing Contrast Agent;</li>\n      <li>\n        Radiological/Contrast Media (Ionic);</li>\n      <li>\n        Radiological/Contrast Media, Paramagnetic Agent</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F21879444\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>CNS  imaging:</b> IV: 0.2 mL/kg (0.1 mmol/kg); may begin imaging immediately after administration.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50990729\" class=\"block dora drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment (Adult)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">No dosage adjustment recommended; however, use with caution. The risk for developing nephrogenic systemic fibrosis (NSF) increases as renal function decreases.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hemodialysis: Gadoterate meglumine is removed by hemodialysis.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50988095\" class=\"block doha drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment (Adult)</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F21879443\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=gadoterate-meglumine-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Gadoterate meglumine: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>CNS  imaging:</b> Neonates, Infants, Children, and Adolescents: Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F51112222\" class=\"block dorp drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment (Pediatric)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Children &ge;2 years and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">There are no dosage adjustments provided in the manufacturer's labeling; however, use with caution. Risk for nephrogenic systemic fibrosis (NSF) development increases as renal function decreases.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hemodialysis: Gadoterate meglumine is removed by hemodialysis.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F51112223\" class=\"block dohp drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment (Pediatric)</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F21879453\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22901339\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Dotarem: 5 mmol/10 mL (10 mL); 7.5 mmol/15 mL (15 mL); 10 mmol/20 mL (20 mL); 50 mmol/100 mL (100 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Prefilled Syringe, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Dotarem: 5 mmol/10 mL (10 mL); 7.5 mmol/15 mL (15 mL); 10 mmol/20 mL (20 mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F21879258\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F21879498\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">IV: Administer as an IV bolus injection (by manual injection or power injector). In adults, infuse at a rate of approximately 2 mL/second; in pediatric patients, infuse at a rate of 1 to 2 mL/second. To ensure complete injection of contrast agent, flush line with NS after administration.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">May be a vesicant (higher osmolar contrast media and higher volumes are associated with a higher risk); ensure proper needle or catheter placement prior to and during infusion; avoid extravasation.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Extravasation management:</b> If extravasation occurs, stop infusion immediately and disconnect (leave cannula/needle in place); gently aspirate extravasated solution (do <b>NOT</b> flush the line); remove needle/cannula; elevate extremity. Consider initiating hyaluronidase antidote if indicated (eg, for extravasated volumes &gt;50 mL [Reynolds 2014]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Hyaluronidase:</i> Intradermal or SubQ: Inject a total of 1 mL (15 units/mL) as five separate 0.2 mL injections (using a 25-gauge needle) into area of extravasation at the leading edge in a clockwise manner (MacCara 1983; Zenk 1981) <b>or</b> injection of a total of 5 mL (150 units/mL) as five separate 1 mL injections around the extravasation site has been also used successfully (Rowlett 2012).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16424029\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>CNS imaging:</b> Contrast medium for magnetic resonance imaging (MRI) in adults, adolescents, and pediatric patients (including term neonates) to detect and visualize areas with disruption of the blood brain barrier (BBB) and/or abnormal vascularity in the brain (intracranial), spine, and associated tissues</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F21879245\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant harm when used in error.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F21964157\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Headache (&le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Nausea (&le;1)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Altered sense of smell, anaphylactoid reaction, anaphylaxis, angioedema, anxiety, bradycardia, bronchospasm, burning sensation, cardiac arrest, cardiac arrhythmia, circulatory shock, coma, conjunctivitis, convulsions, cyanosis, diarrhea, dizziness, drowsiness, dysgeusia, eyelid edema, fatigue, feeling hot, fever, hyperhidrosis, hypersensitivity reaction, hypertension, hypotension, increased lacrimation, increased serum creatinine, inflammation at injection site, injection site pruritus, injection site reaction (including cold, warmth), laryngeal discomfort, laryngospasm, limb pain, malaise, muscle spasm, myasthenia, ocular hyperemia, pain, pain at injection site, palpitations, paresthesia, pharyngeal edema, phlebitis (superficial), presyncope, pruritus, respiratory arrest, sensation of cold, sialorrhea, skin rash, swelling at injection site, syncope, tachycardia, tremor, urticaria, vomiting, weakness</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F21879301\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to gadoterate meglumine or any component of the formulation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F21879319\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Extravasation: May cause injection-site irritation if extravasated into tissue. Avoid extravasation. May be a vesicant (higher osmolar contrast media and higher volumes are associated with a higher risk); ensure proper needle or catheter placement prior to and during administration.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity reactions: Anaphylactic and anaphylactoid reactions have occurred (with cardiovascular, respiratory, or dermatologic involvement); some have involved fatalities due to circulatory collapse. Symptoms typically occurred within minutes of administration and resolved with prompt emergency treatment. Prior to administration, assess patients for history of contrast media reaction, bronchial asthma, and/or allergic disorders. Monitor patients closely during and after infusion. If hypersensitivity occurs, begin immediate management. Appropriate equipment, trained personnel and emergency medications should be available during use.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Nephrogenic systemic fibrosis: <b>[US Boxed Warning]: Gadolinium-based contrast agents (GBCAs) increase the risk for nephrogenic systemic fibrosis (NSF) in patients with impaired elimination of the agents; avoid use unless GBCA enhanced imaging is essential for diagnostic purposes. The risk is highest in patients with acute kidney injury or chronic, severe renal disease (GFR &lt;30 mL/minute/1.73 m<sup>2</sup>). NSF may result in debilitating or fatal systemic fibrosis affecting the skin, muscle, and internal organs. Prior to administration, screen all patients for acute kidney injury or other conditions which may reduce renal function; estimate glomerular filtration rate in patients at risk for chronic declines in renal function (eg, age &gt;60, chronic hypertension, diabetes). Do not exceed the recommended dose and allow a sufficient interval between readministration in patients at risk for NSF.</b> The risk for NSF appears lower in patients with chronic moderate renal disease (GFR 30 to 59 mL/minute/1.73 m<sup>2</sup>) and little, if any, in patients with chronic mild renal disease (GFR 60 to 89 mL/minute/1.73 m<sup>2</sup>). In patients receiving hemodialysis, consider prompt initiation of hemodialysis following administration. If NSF occurs, report to manufacturer or the Food and Drug Administration.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Dose-dependent acute kidney injury has occurred in patients with chronic renal insufficiency following use of gadolinium agents; administer the lowest dose necessary for adequate imaging. Evaluate renal function in all patients; consider follow-up assessment of renal function in patients with a history of renal dysfunction.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24674118\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24674115\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=88898&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:0em;display:inline\">There are no known significant interactions.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F21879279\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events were not observed in animal reproduction studies. Gadolinium-based contrast agents cross the placenta; in general, their use in pregnant women is controversial (ACOG 2016). Use should be avoided unless critical for the care of the mother or fetus and it is not prudent to wait until after pregnancy. Agents with a low risk for development of nephrogenic systemic fibrosis should be used at the lowest effective dose (ACR 2015).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F21879300\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Gadolinium-based contrast agents are present in breast milk (ACR 2015). Because of the low expected excretion into breast milk and the low absorption from an infant's GI tract, other sources note breastfeeding may be continued without interruption after use (ACOG 2016; ACR 2015). Theoretically, the taste of milk could be altered if it contains contrast media. Women who prefer to temporarily withhold breastfeeding can pump and store milk prior to the procedure and abstain from breastfeeding for 12 to 24 hours (ACR 2015). The manufacturer recommends caution be used if administered to breastfeeding women.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F21879502\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Signs of hypersensitivity (during and after administration); renal function (prior to administration); signs/symptoms of NSF (eg, burning, itching, swelling, hardening and/or tightening of skin, joint stiffness, deep hip or rib bone pain, muscle weakness, limited range of motion, and/or yellowed/raised spots on whites of eye); monitor injection site for signs/symptoms of extravasation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F21879402\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Gadoterate meglumine is a gadolinium-containing paramagnetic macrocyclic ionic contrast agent. Exposure to an external magnetic field induces a local magnetic moment in exposed tissues. This local magnetism enhances water proton relaxation in the vicinity, resulting in an increase in signal intensity (brightness) in tissues. Does not cross intact blood-brain barrier, therefore will only enhance brain lesions if the blood-brain barrier is disrupted or if there is abnormal vascularity.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F21879418\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Onset of action: Imaging may begin immediately after administration</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: 179 &plusmn; 26 mL/kg (female); 211 &plusmn; 35 mL/kg (male); does not cross intact blood-brain barrier</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: None</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Not metabolized</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: 1.4 &plusmn; 0.2 hours (female); 2 &plusmn; 0.7 hours (male)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (72.9% &plusmn; 17% female; 85.4 &plusmn; 9.7% male)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F51196084\" class=\"block phksp drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics: Additional Considerations</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Renal function impairment: Following a single 0.1 mmol/kg dose to patients with creatinine clearances of 10-60 mL/minute, gadolinium elimination was delayed. Total clearance decreased in correlation with the degree of renal impairment. Cumulative urinary excretion was ~77% over 48 hours in patients with moderate impairment and ~68% over 72 hours in patients with severe impairment, compared to ~93% over 24 hours in patients with normal renal function.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F23613357\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Dotarem Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mmol/10 mL (10 mL): $60.36</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">7.5 mmol/15 mL (15 mL): $90.54</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mmol/20 mL (20 mL): $120.72</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mmol/100 mL (100 mL): $573.42</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution Prefilled Syringe</b> (Dotarem Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mmol/10 mL (10 mL): $67.60</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">7.5 mmol/15 mL (15 mL): $99.60</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mmol/20 mL (20 mL): $130.38</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F23777443\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Dotarem (AE, AR, AT, AU, BE, BR, CL, CY, CZ, DE, DK, EC, EE, EG, ES, FI, FR, GR, HR, HU, IE, IL, IN, IT, KR, KW, LB, LT, LU, NL, NO, NZ, PL, PT, QA, RO, RU, SA, SE, SG, SI, SK, TH, TR, VE)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    American College of Obstetricians and Gynecologists (ACOG) Committee on Obstetric Practice. Committee Opinion No. 656: guidelines for diagnostic imaging during pregnancy and lactation. <i>Obstet Gynecol</i>. 2016;127(2):e75-e80. doi:10.1097/AOG.0000000000001316.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gadoterate-meglumine-drug-information/abstract-text/26942391/pubmed\" target=\"_blank\" id=\"26942391\">26942391</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American College of Radiology Committee on Drugs and Contrast Media. ACR Manual on Contrast Media. Version 10.1. http://www.acr.org/~/media/ACR/Documents/PDF/QualitySafety/Resources/Contrast%20Manual/2015_Contrast_Media.pdf. Published 2015. Accessed April 15, 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Anzalone N, Scarabino T, Venturi C, et al. Cerebral neoplastic enhancing lesions: multicenter, randomized, crossover intraindividual comparison between gadobutrol (1.0M) and gadoterate meglumine (0.5M) at 0.1 mmol Gd/kg body weight in a clinical setting. <i>Eur J Radiol</i>. 2013;82(1):139-145.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gadoterate-meglumine-drug-information/abstract-text/21890295/pubmed\" target=\"_blank\" id=\"21890295\">21890295</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"12386778\"></a>Bellin MF, Jakobsen JA, Tomassin I, et al; Contrast Media Safety Committee Of The European Society Of Urogenital Radiology. Contrast medium extravasation injury: guidelines for prevention and management. <i>Eur Radiol</i>. 2002;12(11):2807-2812. doi: 10.1007/s00330-002-1630-9<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gadoterate-meglumine-drug-information/abstract-text/12386778/pubmed\" target=\"_blank\" id=\"12386778\">12386778</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dotarem (gadoterate meglumine) [prescribing information]. Princeton, NJ: Guerbet LLC; August 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dotarem pharmacy bulk package (gadoterate meglumine) [prescribing information]. Princeton, NJ: Guerbet LLC; August 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Expert Panel on MR Safety, Kanal E, Barkovich AJ, et al. ACR guidance document on MR safe practices: 2013. <i>J Magn Reson Imaging</i>. 2013;37(3):501-530.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gadoterate-meglumine-drug-information/abstract-text/23345200/pubmed\" target=\"_blank\" id=\"23345200\">23345200</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Janus N, Launay-Vacher V, Karie S, et al. Prevalence of nephrogenic systemic fibrosis in renal insufficiency patients: results of the FINEST study. <i>Eur J Radiol</i>. 2010;73(2):357-359.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gadoterate-meglumine-drug-information/abstract-text/19128909/pubmed\" target=\"_blank\" id=\"19128909\">19128909</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    MacCara ME. Extravasation: a hazard of intravenous therapy. <i>Drug Intell Clin Pharm</i>. 1983;17(10):713-717.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gadoterate-meglumine-drug-information/abstract-text/6628223/pubmed\" target=\"_blank\" id=\"6628223\">6628223</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"24420913\"></a>Reynolds PM, MacLaren R, Mueller SW, Fish DN, Kiser TH. Management of extravasation injuries: a focused evaluation of noncytotoxic medications. <i>Pharmacotherapy</i>. 2014;34(6):617-32. doi: 10.1002/phar.1396.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gadoterate-meglumine-drug-information/abstract-text/24420913/pubmed\" target=\"_blank\" id=\"24420913\">24420913</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rowlett J. Extravasation of contrast media managed with recombinant human hyaluronidase. <i>Am J Emerg Med</i>. 2012;30(9):2102.e1-3.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gadoterate-meglumine-drug-information/abstract-text/22633726/pubmed\" target=\"_blank\" id=\"22633726\">22633726</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zenk KE. Management of intravenous extravasations. <i>Infusion</i>. 1981;5(4):77-79.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 88898 Version 72.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Special Alerts\" href=\"#F49334639\" class=\"outlineLink\">Special Alerts</a></li><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F16424023\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F21879247\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F50906584\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F16424027\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F21879444\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment (Adult)\" href=\"#F50990729\" class=\"outlineLink\">Dosing: Renal Impairment (Adult)</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment (Adult)\" href=\"#F50988095\" class=\"outlineLink\">Dosing: Hepatic Impairment (Adult)</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F21879443\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment (Pediatric)\" href=\"#F51112222\" class=\"outlineLink\">Dosing: Renal Impairment (Pediatric)</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment (Pediatric)\" href=\"#F51112223\" class=\"outlineLink\">Dosing: Hepatic Impairment (Pediatric)</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F21879453\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F22901339\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F21879258\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F21879498\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F16424029\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F21879245\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F21964157\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F21879301\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F21879319\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F24674118\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F24674115\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F21879279\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F21879300\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F21879502\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F21879402\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F21879418\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics: Additional Considerations\" href=\"#F51196084\" class=\"outlineLink\">Pharmacodynamics/Kinetics: Additional Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F23613357\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F23777443\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/88898|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=gadoterate-meglumine-patient-drug-information\" class=\"drug drug_patient\">Gadoterate meglumine: Patient drug information</a></li><li><a href=\"topic.htm?path=gadoterate-meglumine-pediatric-drug-information\" class=\"drug drug_pediatric\">Gadoterate meglumine: Pediatric drug information</a></li></ul></div></div>","javascript":null}